Form 4: Insmed CLO Michael Smith Executes Stock Sale

Insmed Incorporated Chief Legal Officer Michael Smith sold 2,159 shares of common stock to satisfy tax obligations.

Summary

• Michael Smith, Chief Legal Officer of Insmed Inc, sold 2,159 shares of common stock on June 3, 2026.
• The shares were sold at a price of $102.27 per share.
• Following the transaction, the reporting person retains beneficial ownership of 39,454 shares of Insmed common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is purely administrative and related to tax obligations rather than a discretionary divestment.

Positives

• The transaction was routine and specifically executed to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Negatives

• The sale represents a reduction in the direct equity stake held by a key member of the executive leadership team.

Risks

• None identified; this is a standard administrative transaction for tax compliance.

Future Outlook

No forward-looking guidance or strategic outlook provided in this document.

Management Comments

• The filing notes that the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

Industry Context

StockSavvy.ai notes that executive stock sales to cover tax liabilities upon RSU vesting are standard corporate practice in the biotechnology sector and do not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation and tax compliance practices observed across the S&P 500 and NASDAQ-listed biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was for tax compliance purposes.

Next Steps

• None indicated.

Key Dates

Keywords

Insmed, INSM, Insider Trading, Form 4, Biotechnology, Executive Compensation